SAME SAME BUT DIFFERENT? RISK OF DAA THERAPY FAILURE IN REAL-LIFE HCV/HIV COINFECTION
Directly-acting agents (DAA) against HCV have impressively improved treatment of chronic hepatitis C coinfection. However, relapses still occur. Therefore we assessed the influence of traditional risk factors on treatment outcome in HCV/HIV coinfected patients in the German hepatitis C cohort (GECCO). The GECCO cohort is a multicenter cohort from 9 sites in Germany. All HCV/HIV…